期刊
FRONTIERS IN BIOSCIENCE-LANDMARK
卷 12, 期 -, 页码 3483-3501出版社
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/2329
关键词
hypoxia; tumor; radiosensitizer; bioreductive prodrug; radiation-activated prodrug; review
资金
- NCI NIH HHS [T32 CA009151] Funding Source: Medline
This review focuses on the recent development of hypoxia-activated cytotoxins. Such drugs are prodrugs activated to cytotoxic products in the hypoxic environment of solid tumors (so-called bioreductive prodrugs), but can also be activated by radiation (radiation-activated prodrugs). These compounds grew out of research on hypoxic radiosensitizers, which are compounds that can overcome the radiation resistance of hypoxic cells, and we will discuss this area also. The advantages and limitations of each class of the hypoxia-activated cytotoxins are discussed. In addition we will discuss a novel method of targeting drugs to tumors based on anaerobic bacteria, the so-called clostridia-directed enzyme prodrug therapy or CDEPT, which also exploits the hypoxic environment of solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据